Availability of Draft Toxicological Profiles: Antimony; 2,4-D; Molybdenum; Silica, 27066-27067 [2017-12161]
Download as PDF
nlaroche on DSK30NT082PROD with NOTICES
27066
Federal Register / Vol. 82, No. 112 / Tuesday, June 13, 2017 / Notices
Regulatory Affairs, Office of
Management and Budget, Attention:
Desk Officer for the Federal Trade
Commission, New Executive Office
Building, Docket Library, Room 10102,
725 17th Street NW., Washington, DC
20503. Comments sent to OMB by U.S.
postal mail are subject to delays due to
heightened security precautions. Thus,
comments instead can also be sent via
email to wliberante@omb.eop.gov.
Because your comment will be placed
on the publicly accessible FTC Web site
at https://www.ftc.gov/, you are solely
responsible for making sure that your
comment does not include any sensitive
or confidential information. In
particular, your comment should not
include any sensitive personal
information, such as your or anyone
else’s Social Security number; date of
birth; driver’s license number or other
state identification number, or foreign
country equivalent; passport number;
financial account number; or credit or
debit card number. You are also solely
responsible for making sure that your
comment does not include any sensitive
health information, such as medical
records or other individually
identifiable health information. In
addition, your comment should not
include any ‘‘trade secret or any
commercial or financial information
which . . . is privileged or
confidential’’—as provided by Section
6(f) of the FTC Act, 15 U.S.C. 46(f), and
FTC Rule 4.10(a)(2), 16 CFR 4.10(a)(2)—
including in particular competitively
sensitive information such as costs,
sales statistics, inventories, formulas,
patterns, devices, manufacturing
processes, or customer names.
Comments containing material for
which confidential treatment is
requested must be filed in paper form,
must be clearly labeled ‘‘Confidential,’’
and must comply with FTC Rule 4.9(c).
In particular, the written request for
confidential treatment that accompanies
the comment must include the factual
and legal basis for the request, and must
identify the specific portions of the
comment to be withheld from the public
record. See FTC Rule 4.9(c). Your
comment will be kept confidential only
if the General Counsel grants your
request in accordance with the law and
the public interest. Once your comment
has been posted on the public FTC Web
site—as legally required by FTC Rule
4.9(b)—we cannot redact or remove
your comment from the FTC Web site,
unless you submit a confidentiality
request that meets the requirements for
such treatment under FTC Rule 4.9(c),
and the General Counsel grants that
request.
VerDate Sep<11>2014
14:58 Jun 12, 2017
Jkt 241001
Visit the FTC Web site to read this
Notice. The FTC Act and other laws that
the Commission administers permit the
collection of public comments to
consider and use in this proceeding as
appropriate. The Commission will
consider all timely and responsive
public comments that it receives on or
before July 13, 2017. For information on
the Commission’s privacy policy,
including routine uses permitted by the
Privacy Act, see https://www.ftc.gov/
site-information/privacy-policy.
David C. Shonka,
Acting General Counsel.
[FR Doc. 2017–12191 Filed 6–12–17; 8:45 am]
BILLING CODE 6750–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Agency for Toxic Substances and
Disease Registry
[Docket No. ATSDR–2014–0002]
Availability of Draft Toxicological
Profiles: Antimony; 2,4-D;
Molybdenum; Silica
Agency for Toxic Substances
and Disease Registry (ATSDR),
Department of Health and Human
Services (HHS).
ACTION: Notice of availability, and
request for comment.
AGENCY:
The Agency for Toxic
Substances and Disease Registry
(ATSDR), within the Department of
Health and Human Services (HHS)
announces the availability of
Toxicological Profiles for review and
comment. All toxicological profiles
issued as ‘‘Drafts for Public Comment’’
represent ATSDR’s best efforts to
provide important toxicological
information on priority hazardous
substances. ATSDR is seeking public
comments and additional information or
reports on studies about the health
effects of these four substances for
review and potential inclusion in the
profiles.
Although ATSDR considers key
studies for these substances during the
profile development process, this
document solicits any relevant,
additional studies. ATSDR will evaluate
the quality and relevance of such data
or studies for possible inclusion into the
profile. ATSDR remains committed to
providing a public comment period for
these documents as a means to best
serve public health and the public.
DATES: Comments must be submitted by
September 11, 2017.
SUMMARY:
PO 00000
Frm 00031
Fmt 4703
Sfmt 4703
You may submit comments,
identified by docket number ATSDR–
2014–0002, by any of the following
methods:
• Internet: Access the Federal
eRulemaking Portal at
www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: Division of Toxicology and
Human Health Sciences, Agency for
Toxic Substances and Disease Registry,
1600 Clifton Rd. NE., MS F–57, Atlanta,
GA 30329.
Instructions: All submissions must
include the agency name and docket
number for this notice. All relevant
comments will be posted without
change. This means that no confidential
business information or other
confidential information should be
submitted in response to this notice.
FOR FURTHER INFORMATION CONTACT:
Commander Jessilynn B. Taylor,
Division of Toxicology and Human
Health Sciences, Agency for Toxic
Substances and Disease Registry, 1600
Clifton Rd. NE., MS F–57, Atlanta, GA
30329, Email: jxt1@cdc.gov; Phone:
770–488–3313.
SUPPLEMENTARY INFORMATION: The
Superfund Amendments and
Reauthorization Act of 1986 (SARA) [42
U.S.C. 9601 et seq.] amended the
Comprehensive Environmental
Response, Compensation, and Liability
Act of 1980 (CERCLA or Superfund) [42
U.S.C. 9601 et seq.] by establishing
certain requirements for ATSDR and the
U.S. Environmental Protection Agency
(EPA) regarding hazardous substances
that are most commonly found at
facilities on the CERCLA National
Priorities List (NPL). Among these
statutory requirements is a mandate for
the Administrator of ATSDR to prepare
toxicological profiles for each substance
included on the priority list of
hazardous substances [also called the
Substance Priority List (SPL)]. This list
identifies 275 hazardous substances that
ATSDR and EPA have determined pose
the most significant potential threat to
human health. The SPL is available
online at www.atsdr.cdc.gov/spl.
In addition, CERCLA provides ATSDR
with the authority to prepare
toxicological profiles for substances not
found on the SPL. CERCLA authorizes
ATSDR to establish and maintain
inventory of literature, research, and
studies on the health effects of toxic
substances (CERCLA Section
104(i)(1)(B)); to respond to requests for
health consultations (CERCLA Section
104(i)(4)); and to support the sitespecific response actions conducted by
the agency.
ADDRESSES:
E:\FR\FM\13JNN1.SGM
13JNN1
Federal Register / Vol. 82, No. 112 / Tuesday, June 13, 2017 / Notices
Availability
The Draft Toxicological Profiles are
available online at https://
www.atsdr.cdc.gov/ToxProfiles and at
www.regulations.gov, Docket No.
ATSDR–2014–0002.
Pamela I. Protzel Berman,
Director, Office of Policy, Planning and
Evaluation, Agency for Toxic Substances and
Disease Registry.
[FR Doc. 2017–12161 Filed 6–12–17; 8:45 am]
BILLING CODE 4163–70–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[CMS–3343–PN]
Medicare and Medicaid Programs:
Application From the American
Osteopathic Association/Healthcare
Facilities Accreditation Program
(AOA–HFAP) for Continued CMS
Approval of Its Ambulatory Surgical
Center Accreditation Program
Centers for Medicare and
Medicaid Services, HHS.
ACTION: Notice with request for
comment.
AGENCY:
This proposed notice
acknowledges the receipt of an
application from the American
Osteopathic Association/Healthcare
Facilities Accreditation Program (AOA–
HFAP) for continued recognition as a
national accrediting organization for
Ambulatory Surgical Centers that wish
to participate in the Medicare or
Medicaid programs.
DATES: To be assured consideration,
comments must be received at one of
the addresses provided below, no later
than 5 p.m. on July 13, 2017.
ADDRESSES: In commenting, please refer
to file code CMS–3343–PN. Because of
staff and resource limitations, we cannot
accept comments by facsimile (FAX)
transmission.
You may submit comments in one of
four ways (please choose only one of the
ways listed):
1. Electronically. You may submit
electronic comments on this regulation
to https://www.regulations.gov. Follow
the ‘‘Submit a comment’’ instructions.
2. By regular mail. You may mail
written comments to the following
address ONLY: Centers for Medicare &
Medicaid Services, Department of
Health and Human Services, Attention:
CMS–3343–PN, P.O. Box 8010,
Baltimore, MD 21244–8010.
nlaroche on DSK30NT082PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
14:58 Jun 12, 2017
Jkt 241001
Please allow sufficient time for mailed
comments to be received before the
close of the comment period.
3. By express or overnight mail. You
may send written comments to the
following address ONLY: Centers for
Medicare & Medicaid Services,
Department of Health and Human
Services, Attention: CMS–3343–PN,
Mail Stop C4–26–05, 7500 Security
Boulevard, Baltimore, MD 21244–1850.
4. By hand or courier. Alternatively,
you may deliver (by hand or courier)
your written comments ONLY to the
following addresses:
a. For delivery in Washington, DC—
Centers for Medicare & Medicaid
Services, Department of Health and
Human Services, Room 445–G, Hubert
H. Humphrey Building, 200
Independence Avenue SW.,
Washington, DC 20201.
(Because access to the interior of the
Hubert H. Humphrey Building is not
readily available to persons without
Federal government identification,
commenters are encouraged to leave
their comments in the CMS drop slots
located in the main lobby of the
building. A stamp-in clock is available
for persons wishing to retain a proof of
filing by stamping in and retaining an
extra copy of the comments being filed.)
b. For delivery in Baltimore, MD—
Centers for Medicare & Medicaid
Services, Department of Health and
Human Services, 7500 Security
Boulevard, Baltimore, MD 21244–1850.
If you intend to deliver your
comments to the Baltimore address, call
telephone number (410) 786–9994 in
advance to schedule your arrival with
one of our staff members.
Comments erroneously mailed to the
addresses indicated as appropriate for
hand or courier delivery may be delayed
and received after the comment period.
For information on viewing public
comments, see the beginning of the
SUPPLEMENTARY INFORMATION section.
FOR FURTHER INFORMATION CONTACT:
Monda Shaver, (410) 786–0310, Erin
McCoy, (410) 786–2337, or Patricia
Chmielewski, (410) 786–6899.
SUPPLEMENTARY INFORMATION:
Inspection of Public Comments: All
comments received before the close of
the comment period are available for
viewing by the public, including any
personally identifiable or confidential
business information that is included in
a comment. We post all comments
received before the close of the
comment period on the following Web
site as soon as possible after they have
been received: https://
www.regulations.gov. Follow the search
PO 00000
Frm 00032
Fmt 4703
Sfmt 4703
27067
instructions on that Web site to view
public comments.
Comments received timely will also
be available for public inspection as
they are received, generally beginning
approximately 3 weeks after publication
of a document, at the headquarters of
the Centers for Medicare & Medicaid
Services, 7500 Security Boulevard,
Baltimore, Maryland 21244, Monday
through Friday of each week from 8:30
a.m. to 4 p.m. To schedule an
appointment to view public comments,
phone 1–800–743–3951.
I. Background
Under the Medicare program, eligible
beneficiaries may receive covered
services from an Ambulatory Surgical
Center (ASC) provided certain
requirements are met. Section
1832(a)(2)(F)(i) of the Social Security
Act (the Act) establishes distinct criteria
for facilities seeking designation as an
ASC. Regulations concerning provider
agreements are at 42 CFR part 489 and
those pertaining to activities relating to
the survey and certification of facilities
are at 42 CFR part 488. The regulations
at 42 CFR part 416 specify the
conditions that an ASC must meet in
order to participate in the Medicare
program, the scope of covered services,
and the conditions for Medicare
payment for ASCs.
Generally, to enter into an agreement,
an ASC must first be certified by a State
survey agency as complying with the
conditions or requirements set forth in
part 416 of our Medicare regulations.
Thereafter, the ASC is subject to regular
surveys by a State survey agency to
determine whether it continues to meet
these requirements.
Section 1865(a)(1) of the Act provides
that, if a provider entity demonstrates
through accreditation by a Centers for
Medicare & Medicaid Services (CMS)
approved national accrediting
organization (AO) that all applicable
Medicare conditions are met or
exceeded, we may deem those provider
entities as having met the requirements.
Accreditation by an AO is voluntary and
is not required for Medicare
participation.
If an AO is recognized by the
Secretary of the Department of Health
and Human Services as having
standards for accreditation that meet or
exceed Medicare requirements, any
provider entity accredited by the
national accrediting body’s approved
program may be deemed to meet the
Medicare conditions. An AO applying
for approval of its accreditation program
under part 488, subpart A, must provide
CMS with reasonable assurance that the
AO requires the accredited provider
E:\FR\FM\13JNN1.SGM
13JNN1
Agencies
[Federal Register Volume 82, Number 112 (Tuesday, June 13, 2017)]
[Notices]
[Pages 27066-27067]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-12161]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Agency for Toxic Substances and Disease Registry
[Docket No. ATSDR-2014-0002]
Availability of Draft Toxicological Profiles: Antimony; 2,4-D;
Molybdenum; Silica
AGENCY: Agency for Toxic Substances and Disease Registry (ATSDR),
Department of Health and Human Services (HHS).
ACTION: Notice of availability, and request for comment.
-----------------------------------------------------------------------
SUMMARY: The Agency for Toxic Substances and Disease Registry (ATSDR),
within the Department of Health and Human Services (HHS) announces the
availability of Toxicological Profiles for review and comment. All
toxicological profiles issued as ``Drafts for Public Comment''
represent ATSDR's best efforts to provide important toxicological
information on priority hazardous substances. ATSDR is seeking public
comments and additional information or reports on studies about the
health effects of these four substances for review and potential
inclusion in the profiles.
Although ATSDR considers key studies for these substances during
the profile development process, this document solicits any relevant,
additional studies. ATSDR will evaluate the quality and relevance of
such data or studies for possible inclusion into the profile. ATSDR
remains committed to providing a public comment period for these
documents as a means to best serve public health and the public.
DATES: Comments must be submitted by September 11, 2017.
ADDRESSES: You may submit comments, identified by docket number ATSDR-
2014-0002, by any of the following methods:
Internet: Access the Federal eRulemaking Portal at
www.regulations.gov. Follow the instructions for submitting comments.
Mail: Division of Toxicology and Human Health Sciences,
Agency for Toxic Substances and Disease Registry, 1600 Clifton Rd. NE.,
MS F-57, Atlanta, GA 30329.
Instructions: All submissions must include the agency name and
docket number for this notice. All relevant comments will be posted
without change. This means that no confidential business information or
other confidential information should be submitted in response to this
notice.
FOR FURTHER INFORMATION CONTACT: Commander Jessilynn B. Taylor,
Division of Toxicology and Human Health Sciences, Agency for Toxic
Substances and Disease Registry, 1600 Clifton Rd. NE., MS F-57,
Atlanta, GA 30329, Email: jxt1@cdc.gov; Phone: 770-488-3313.
SUPPLEMENTARY INFORMATION: The Superfund Amendments and Reauthorization
Act of 1986 (SARA) [42 U.S.C. 9601 et seq.] amended the Comprehensive
Environmental Response, Compensation, and Liability Act of 1980 (CERCLA
or Superfund) [42 U.S.C. 9601 et seq.] by establishing certain
requirements for ATSDR and the U.S. Environmental Protection Agency
(EPA) regarding hazardous substances that are most commonly found at
facilities on the CERCLA National Priorities List (NPL). Among these
statutory requirements is a mandate for the Administrator of ATSDR to
prepare toxicological profiles for each substance included on the
priority list of hazardous substances [also called the Substance
Priority List (SPL)]. This list identifies 275 hazardous substances
that ATSDR and EPA have determined pose the most significant potential
threat to human health. The SPL is available online at
www.atsdr.cdc.gov/spl.
In addition, CERCLA provides ATSDR with the authority to prepare
toxicological profiles for substances not found on the SPL. CERCLA
authorizes ATSDR to establish and maintain inventory of literature,
research, and studies on the health effects of toxic substances (CERCLA
Section 104(i)(1)(B)); to respond to requests for health consultations
(CERCLA Section 104(i)(4)); and to support the site-specific response
actions conducted by the agency.
[[Page 27067]]
Availability
The Draft Toxicological Profiles are available online at https://www.atsdr.cdc.gov/ToxProfiles and at www.regulations.gov, Docket No.
ATSDR-2014-0002.
Pamela I. Protzel Berman,
Director, Office of Policy, Planning and Evaluation, Agency for Toxic
Substances and Disease Registry.
[FR Doc. 2017-12161 Filed 6-12-17; 8:45 am]
BILLING CODE 4163-70-P